The contribution good corporate partnerships make to the coffers of biotech companies can't be under-estimated in sluggish financing markets, a point that is illustrated by Viagene Inc.'s collaboration with Green Cross Corp.

That deal, which last week was renewed for two more years, already has provided money equivalent to one good-sized public offering. The ultimate contribution from the deal, including milestones, will be $50-60 million.